Best Life Sciences Companies in Baden Wurttemberg, Germany
The 204 best Life Sciences companies in Baden Wurttemberg, Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CureVac.
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
Ranked: Best Life Sciences companies in Baden Wurttemberg
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CureVac Developer of mRNA-based therapeutics against cancer and infectious diseases 55Patents top 20%Funding top 28%Moat top 29%Innovation top 32% All 11 signals ▾Patentstop 20% Fundingtop 28% Moattop 29% Innovationtop 32% Partnerstop 41% Markettop 43% Newstop 45% Talenttop 49% Techbottom 49% Globalbottom 46% Growthbottom 38% Patents: 1,737 patents matched (strict assignee match) · 461 filings since 2022 vs 745 in 2017-21 Funding: Raised $975M across 14 rounds · 14 rounds over 23 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $975M | 69 mo ago | 648 648 → 678 (+5%) · sector median -4% | Florian Mulbe Co-Founder & CPO | WordPressApple iCloud MailMicrosoft 365+20 | Top 5M | 1,737 patents mRNA therapeutics and vaccine delivery via lipid nanoparticle platforms | — |
| 2 | Immatics Developer of T -cell-based immunotherapies for the treatment of cancer 76Product top 14%Funding top 23%News top 23%Patents top 30% All 10 signals ▾Producttop 14% Fundingtop 23% Newstop 23% Patentstop 30% Techtop 31% Growthtop 32% Moattop 32% Innovationtop 39% Markettop 41% Globaltop 50% Product: 6 distinct product lines · Company stage: Public Funding: Raised $236M across 7 rounds · 7 rounds over 22 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 76/100 | $236M | 34 mo ago | 198 | — | WordPressApple iCloud MailMicrosoft 365+31 | Top 5M | 43 patents Engineering and selection of antigen-specific T cells for adoptive immunotherapy | — |
| 3 | Curetis Provider of molecular diagnostics platform to detect infectious diseases | $127M | 68 mo ago | 55 | Raju Jha CEO | Wix eCommerceWixSentry+10 | Top 50M | 79 patents Automated nucleic acid extraction and sample lysis technologies for molecular diagnostic platforms. | — |
| 4 | Retina Implant Subretinal implants for partially sighted and blind patients | $46M | 123 mo ago | 10 | — | — | — | 62 patents Sub‑retinal optical‑electrical prosthetic devices for vision restoration | — |
| 5 | Allecra Developer of antibiotics for the treatment of multi-drug-resistant bacterial infections | $44M | 120 mo ago | 10 | Andreas Kranzusch Managing Director | — | — | — | — |
| 6 | HepaRegeniX Developer of small molecule therapeutics 42Talent top 28%Patents top 29%Funding top 32%Innovation top 38% All 9 signals ▾Talenttop 28% Patentstop 29% Fundingtop 32% Innovationtop 38% Moattop 39% Globalbottom 44% Growthbottom 42% Marketbottom 29% Newsbottom 18% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Patents: 76 patents matched (strict assignee match) · 42 filings since 2022 vs 34 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $38M | 14 mo ago | 9 | Lars Zender Co-Founder | — | — | 76 patents Small-molecule kinase inhibitors for liver regeneration and cancer therapy targeting MKK4 and related kinases. | — |
| 7 | SpinDiag Developer of point-of-care system for screening drug-resistant pathogens | $28M | 44 mo ago | 74 | Frank Schwemmer Co-Founder | — | — | 39 patents Magnetic‑rotational sample preparation and lysis for nucleic‑acid extraction and analysis | — |
| 8 | CorTec Manufacturer of active implantable neurotechnology devices, components, and sub-assemblies | $22M | 40 mo ago | 68 68 → 90 (+32%) · sector median -4% | Martin Schuettler Co-Founder | WordPressMySQLPHP+19 | Top 10M | 148 patents Implantable neural interfaces with hermetic, impact‑protected packaging and adaptive stimulation | 1 launch |
| 9 | Acousia Therapeutics Developer of small molecule therapeutics supporting cellular regeneration to reverse hearing loss | $15M | 29 mo ago | 4 | Christoph Antz CEO | WordPressMySQLPHP+14 | Top 50M | 84 patents Potassium channel opener drugs and their synthesis, plus gel delivery formulations. | 1 partnership |
| 10 | Atriva Therapeutics Re-purposing MEK inhibitors to treat viral infections including COVID-19 and influenza | $14M | 67 mo ago | 13 | Rainer Lichtenberger Advisor to the CEO | — | — | 112 patents MEK kinase inhibitor therapeutics for viral, bacterial, and hantavirus infections | — |
| 11 | Amcure Development of a novel compound for the treatment of metastasizing cancers | $13M | 114 mo ago | 7 | — | — | — | 42 patents Therapeutic cyclic peptides targeting CD44v6 for cancer and angiogenesis treatment | — |
| 12 | PeakData Provider of a software platform to identify and analyze key opinion leaders | $12M | 45 mo ago | 55 | Michael Feldman Co-Founder | WordPressMySQLPHP+17 | Top 50M | — | — |
| 13 | Greenovation Biopharmaceuticals Biopharma company manufacturing glycoproteins for treatment of orphan diseases | $7M | 234 mo ago | 31 | Gunther Neuhaus Co-Founder | — | — | — | — |
| 14 | Subitec Technology for cultivation of micro algae | $6M | 167 mo ago | 9 | Peter Ripplinger CEO | WordPressMySQLPHP+18 | Top 10M | 11 patents Air‑purifying bioreactors that capture pollutants and generate valuable bioproducts | — |
| 15 | Metrax Automated external defibrillators for emergencies | $6M | 201 mo ago | 77 77 → 43 (-44%) · sector median -4% | — | Cart FunctionalityShopifyVisa+21 | Top 10M | 73 patents Advanced AED systems, rapid deployment logistics, and smart defibrillation electrode technologies | — |
| 16 | ProtaGene Provider of drug development services for cell & gene therapeutic services | $5M | 152 mo ago | 55 | — | WordPressMySQLPHP+26 | Top 10M | — | 1 job opening |
| 17 | Cytena Single cell isolation technology | $5M | 86 mo ago | 71 71 → 62 (-13%) · sector median -4% | Julian Riba CEO | Cart FunctionalityWooCommerceWordPress+27 | Top 5M | 168 patents Microfluidic lab‑on‑a‑chip devices for centrifugation, actuation, particle detection, and cell monitoring | 1 partnership |
| 18 | Biametrics Label-free biosensor technology for analysis of any kind of biomolecular interaction | $4M | 129 mo ago | 11 | — | — | — | 9 patents Optical thin‑film and biosensor analysis of reflection coefficients and molecular interactions | — |
| 19 | Katairo Developer of therapeutics for the treatment of disabling eye indications | $3M | 102 mo ago | — | Wolfgang Klein CEO | — | — | 28 patents Therapeutics targeting lipofuscin accumulation and lysosomal dysfunction for age‑related diseases | — |
| 20 | Efferon Developer of extracorporeal blood purification technologies 19Patents top 45%Innovation top 49%Talent bottom 49%Funding bottom 47% All 7 signals ▾Patentstop 45% Innovationtop 49% Talentbottom 49% Fundingbottom 47% Globalbottom 46% Techbottom 30% Marketbottom 25% Patents: 6 patents matched (strict assignee match) · 6 filings since 2022 vs 0 in 2017-21 Innovation: 6 patents (top 91% of patent-holders) · 6 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 19/100 | $3M | 1 mo ago | — | Alexei Morozov Co-Founder | WordPressMySQLPHP+17 | Top 50M | 6 patents Polymeric sorbents for selective ion removal in water treatment processes | 1 partnership |
| 21 | Dermagnostix Developer of molecular diagnostic tests for skin diseases | $3M | 42 mo ago | 24 | — | WordPressMySQLPHP+18 | Top 50M | 25 patents Patents concentrated in transport & manufacturing processes | 1 job opening · 1 partnership |
| 22 | Multi Channel Systems Tools for Electrophysiology | $3M | 60 mo ago | 68 | Karl-Heinz Boven CEO | DrupalApple iCloud MailMicrosoft 365+14 | Top 5M | — | — |
| 23 | Lonic Liquid Technologies Provider of ionic liquid & nanotechnology coatings for engineering applications | $2M | 27 mo ago | 18 18 → 14 (-22%) · sector median -4% | Thomas Schubert CEO | DrupalPHPSvelte+7 | Top 5M | — | 1 launch |
| 24 | Aquarray Provider of droplet microarray technology for clinical application | $2M | 52 mo ago | 8 | Simon Widmaier CEO | — | — | 2 patents Optical detection methods for analyzing liquids and their components | — |
| 25 | ResuSciTec Therapy for cardiopulmonary resuscitation | $2M | 114 mo ago | 49 49 → 56 (+14%) · sector median -4% | H C Beyersdorf Founder | WordPress Block EditorWordPressApple iCloud Mail+19 | Top 50M | 74 patents Emergency resuscitation training mannequins and extracorporeal cardiac support with therapeutic cooling systems | — |
| 26 | Cellendes Biomimetic hydrogel materials for cell culture applications | $2M | 44 mo ago | — | Brigitte Angres Co-Founder & Managing Director | — | — | 9 patents Hydrogel matrices and cleavable crosslinkers for pancreatic organoid culture | — |
| 27 | Ovesco Endoscopy Developer of endoscopic systems for gastrointestinal disease treatment | $2M | 77 mo ago | 78 | Marc Schurr Founder & CEO | WordPressApple iCloud MailMicrosoft 365+21 | Top 5M | 180 patents Endoscopic accessory and therapeutic delivery systems, including working channel adapters and capsule devices. | 3 launchs |
| 28 | BMG Labtech Provider of a microplate readers instrumentation for life science researchers and companies | $1M | 115 mo ago | 24 | Thomas Rabiger CEO | HubSpot CMS HubSalesforceVideoJS+21 | Top 5M | 25 patents Automated optical detection and focusing for microplate-based bioassay imaging | — |
| 29 | ATG:biosynthetics Provider of a technology platform for gene synthesis | $966K | 134 mo ago | — | Hubert Bernauer Unternehmensinhaber (CEO) | — | — | 10 patents Patents concentrated in health & consumer products | — |
| 30 | Diarect Recombinant and native antigens | $700K | 119 mo ago | 289 | Bodo Liedvogel Co-Founder | — | — | — | — |
| 31 | myPOLS Biotec Provider of engineered DNA polymerases for molecular biology applications | $639K | 74 mo ago | 10 | — | — | — | — | — |
| 32 | Insilico Biotechnology In silico cell models for drug design and discovery. | $624K | 129 mo ago | 29 | — | — | — | 27 patents Machine‑learning‑driven metabolic and bioprocess optimization for cell‑culture production | — |
| 33 | Computomics Provider of data analysis services for next-generation sequencing data for the crop science industry | $551K | 56 mo ago | 13 | — | ContaoMicrosoft WordPHP+6 | Top 50M | — | 1 partnership |
| 34 | macu4 Designs and manufactures passive prosthetics | $311K | 43 mo ago | 12 | Alec Chevrot Co-Founder | WordPressMySQLPHP+13 | Top 10M | — | 1 launch |
| 35 | Avant-garde Materials Simulation Provider of AI/ML-assisted parameter generation for ab-initio-grade force fields | $284K | 40 mo ago | — | Elsa Gheziel-Neumann Human Ressources and Communication Director - CEO | — | — | — | — |
| 36 | Autoimmun Diagnostika Provider of reagents and kits for research purposes | $222K | 89 mo ago | — | Gerlinde Schoellhorn CEO | TYPO3 CMSPHPFreeBSD+6 | Top 5M | 25 patents ELISPOT immunoassay platforms for detecting cellular immune responses to infections. | — |
| 37 | Genaxxon Provider of genomic reagents and other products | $201K | 74 mo ago | — | Norbert Troendle Founder & MD | Cart FunctionalityApache HTTP ServerAmazon Pay+12 | Top 10M | — | 1 job opening |
| 38 | CeGaT Provider of drug research and development services to develop genetic causes of rare diseases | $109K | 125 mo ago | 113 | — | WordPressMySQLPHP+23 | Top 5M | — | — |
Top 12 Life Sciences companies in Baden Wurttemberg
#1
Seed · Tuttlingen, Baden Wurttemberg · founded 2016$2.9Mraised▾
Developer of extracorporeal blood purification technologies. It offers polymeric adsorbents for selective removal of bacterial endotoxins and cytokines, providing extracorporeal treatment for sepsis and multiple organ failure. The company's technology aims to offer a safe and efficient method for stabilizing critically ill patients. Its single-use therapeutic device utilizes polymeric beads surface-modified with an LPS-selective ligand for blood adsorption. The technology has been validated through multiple clinical trials and publications demonstrating its efficacy in treating various conditions, including septic shock and cytokine release syndrome.
- May 2026Seed$2.9M
#2
Series C · Tubingen, Baden Wurttemberg · founded 2017 · 9 employees$37.8Mraised▾
Developer of small molecule therapeutics. Its lead small molecule is an inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4) for the treatment of acute and chronic liver diseases. MKK4 is a key regulator of liver regeneration and suppression of MKK4 gene expression unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
- Apr 2025Series C$24.3M
- Jul 2024Series C$16.2M
- Jan 2020Series B$12.2M
- Jan 2017Series A$9.4M
#3
Public · Tubingen, Baden Wurttemberg · founded 2000 · 198 employees$236.4Mraised▾
Developer of T -cell-based immunotherapies for the treatment of cancer. The company has propriety platform XPRESIDENT is involved in identifying and validating antigens specific to cancer cells and subsequently develops adoptive cell therapies and bispecific TCRs for treating cancer. IMA101, using its proprietary ACTolog approach, which is T-cell products generated from peripheral blood cells with defined target selectivity.
- Jul 2023Post IPO$35M
- Aug 2020Post IPO—
- Oct 2017Series E$58M
- Jan 2016Grant (prize money)$1.4M
#4
Acquired · Tubingen, Baden Wurttemberg · founded 2000 · 648 employees$975.3Mraised▾
Developer of mRNA-based therapeutics against cancer and infectious diseases. It has developed RNAntibody to enable the expression of functional antibodies and antibody-like proteins from mRNA. The lead product includes CV9104, an investigational therapeutic vaccine to treat prostate cancer. The vaccine is injected into the skin to stimulate the body's immune system to destroy prostate cancer cells. The company's other product includes CV8102 for cutaneous myeloma and CV9202 used to treat patients with non-small cell lung cancer.
- Sep 2020Grant (prize money)$299M
- Jul 2020Series F$126M
- Jul 2020Series F$171M
- Jul 2020Conventional Debt$84.3M
#5
Series C · Tubingen, Baden Wurttemberg · founded 2012 · 4 employees$14.6Mraised▾
Developer of small molecule therapeutics supporting cellular regeneration to reverse hearing loss. The company's technology will replace the lost sensory hair cells by cellular regeneration originating from supporting cells. It has set up a screen for repositioning compounds with a cell-protective mode of action. It is currently developing drugs local application, which will restore hearing in patients. The company has identified and patented a small molecule - Otopotin that dedifferentiates otic supporting cells into otic progenitor-like cells that proliferate and redifferentiate into hair cells and supporting cells in vitro. It claims that this therapy will also have the potential to treat the age-related decrease in hearing capacity.
- Jan 2024Series C—
- May 2018Series B$11.9M
- Dec 2016Series A$2.7M
- 2012Seed—
#6
Acquired · Holzgerlingen, Baden Wurttemberg · founded 2007 · 55 employees$127.1Mraised▾
Curetis provides a molecular diagnostics device to detect infectious diseases. The company focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases. The company develops the Unyvero A50 System for the detection of bacterial infections using PCR technology in hospitalized patients. Using a variety of cartridges, diseases such as pneumonia or implant and tissue infections can also be diagnosed within 4–5 hours.
- Sep 2020Grant (prize money)$409.7K
- Jul 2020Conventional Debt$5.7M
- May 2019Series C$1.7M
- May 2019Conventional Debt$5.6M
#7
Series B · Freiburg im Breisgau, Baden Wurttemberg · founded 2016 · 74 employees$27.7Mraised▾
SpinDiag, a spin-off of Hahn-Schickard, develops a point-of-care system. The automated system helps in the screening drug-resistant pathogens. The system, LabDisk, is based on a patented centrifugal-microfluidic technology which provides PCR results directly from patient swab samples.
- Oct 2022Conventional Debt$14.6M
- May 2020Series B$17.8M
- Apr 2020Series B$6.5M
- Nov 2018Series A$3.4M
#8
Series C · Freiburg im Breisgau, Baden Wurttemberg · founded 2010 · 68 employees$21.6Mraised▾
Manufacturer of active implantable neurotechnology devices, components, and sub-assemblies. They offer design, development, and manufacturing services for medical devices. The company provides cuff electrodes, grid electrodes, paddle and strip electrodes, and percutaneous electrodes. Services include electronics and software development, prototyping, testing, and validation. The Brain Interchange System is available for pre-clinical and clinical research.
- Feb 2023Grant (prize money)—
- 2022Series C—
- Nov 2019Series C$14.4M
- Jun 2016Series B—
#9
Funding Raised · Heilbronn, Baden Wurttemberg · founded 2003 · 18 employees$2.3Mraised▾
Provider of ionic liquid & nanotechnology coatings for engineering applications. The products include synthesis, catalysis, analytics, electroplating, biotechnology, sensor applications, and others.
- Mar 2024Grant (prize money)$342K
- Sep 2020Grant (prize money)$243.1K
- May 2020Grant (prize money)$291.3K
- Aug 2017Grant (prize money)$760.2K
#10
Series A · Wustenrot, Baden Wurttemberg · founded 2017 · 55 employees$12.1Mraised▾
Provider of a software platform to identify and analyze key opinion leaders. It offers a SaaS platform that offers pharma companies to learn about physicians and improve agile targeting and segmentation, uses ai driven tools for big data analysis and web mining services enabling the healthcare industry to get insights.
- Aug 2022Series A$12.1M
#11
Series B · Reutlingen, Baden Wurttemberg · founded 2003 · 10 employees$46.4Mraised▾
Retina Implant is a developer of subretinal implants for retinitis pigmentosa, partially sighted and blind patients. It primarily focuses on the development of electronic subretinal implants which picks up light via 1,500 pixels. The signal is boosted by a coil implanted in the skin behind the ear and sent back to the bipolar cells still active on the retina, which in turn send an image to the brain through regular neural circuits.
- Feb 2016Series B$28.4M
- Mar 2011Series A$18M
#12
Series B · Weil am Rhein, Baden Wurttemberg · founded 2013 · 10 employees$44.4Mraised▾
Developer of antibiotics for the treatment of multi-drug-resistant bacterial infections. The company has developed two product candidates cefepime and enmetazobactamto treat Gram-negative multi-drug-resistant infections such as complicated urinary tract infections.
- Jun 2016Series B$24.7M
- Apr 2013Series A$19.7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Germany
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,297 Germany-affiliated papers.
- Heidelberg University85
- German Cancer Research Center49
- Ludwig-Maximilians-Universität München48
- Technical University of Munich43
- Karlsruhe Institute of Technology33
- Gene3→29
- Mutant3→19
- Transcription (linguistics)3→16
- Messenger RNA1→14
- Immune system1→12
- Gene3→20
- Agriculture2→12
- Extracellular1→11
- Immune system1→11
- Transcriptome1→9
- Antibiotic resistance2→9
- Gene1→7
- Agriculture4→9
- Antimicrobial1→4
- Microbiome1→4
Where biotechnology is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in Germany
Germany biotechnology patent filing is cooling — 53,233 filings from 8,000 assignees (2016–2025), led by Immatics Biotechnologies, BASF Plant Science, BASF SE; annual filings 4819→4267.
- Immatics Biotechnologies4875
- BASF Plant Science3993
- BASF SE3545
- Boehringer Ingelheim INT3440
- Merck Patent3137
- MAX Planck Gesellschaft1805
- Evonik Degussa1683
- Amgen RES Munich1665
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.